BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World J Surg Oncol 2021;19:168. [PMID: 34112190 DOI: 10.1186/s12957-021-02280-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Cochrane Hepato-Biliary Group, Jingxin Yan, Manjun Deng, Ting Li, Yaxuan Wang, Jiaxin Wu, LuShun Zhang, Haining Fan. Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2022;2022:CD015389. [ DOI: 10.1002/14651858.CD015389] [Reference Citation Analysis]
2 Yang Y, Yang M, Pang H, Qiu Y, Sun T, Wang T, Shen S, Wang W, Bao J. A Macrophage Differentiation-Mediated Gene: DDX20 as a Molecular Biomarker Encompassing the Tumor Microenvironment, Disease Staging, and Prognoses in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-22. [DOI: 10.1155/2022/9971776] [Reference Citation Analysis]
3 Lai Y, Lee JC, Hung HC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Kao CY, Lee WC. Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections. World J Hepatol 2022; 14(9): 1778-1789 [DOI: 10.4254/wjh.v14.i9.1778] [Reference Citation Analysis]
4 Zhang ZY, Guan J, Wang XP, Hao DS, Zhou ZQ. Outcomes of adolescent and young patients with hepatocellular carcinoma after curative liver resection: a retrospective study. World J Surg Oncol 2022;20:210. [PMID: 35729607 DOI: 10.1186/s12957-022-02658-3] [Reference Citation Analysis]
5 Chen Z, Wang J, Lin Y. Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer: a meta-analysis. World J Surg Oncol 2022;20:182. [PMID: 35668464 DOI: 10.1186/s12957-022-02649-4] [Reference Citation Analysis]
6 Tang M, Huang Y, Liang X, Tao Y, He N, Li Z, Guo J, Gui S. Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance. AAPS PharmSciTech 2022;23:130. [PMID: 35487999 DOI: 10.1208/s12249-022-02214-y] [Reference Citation Analysis]
7 Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [DOI: 10.4251/wjgo.v14.i4.920] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Saito R, Amemiya H, Hosomura N, Kawaida H, Shoda K, Furuya S, Akaike H, Kawaguchi Y, Inoue S, Kono H, Ichikawa D. Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study. World J Surg Oncol 2022;20:90. [PMID: 35317819 DOI: 10.1186/s12957-022-02563-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lin K, Wei F, Huang Q, Lai Z, Zhang J, Chen Q, Jiang Y, Kong J, Tang S, Lin J, Chen Y, Chen J, Zeng Y. Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study. JHC 2022;Volume 9:127-40. [DOI: 10.2147/jhc.s352480] [Reference Citation Analysis]
10 Li L, Cheng N, Huang X, Weng X, Jiao Y, Liu J, Guo W. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis. World J Surg Oncol 2022;20:30. [PMID: 35109883 DOI: 10.1186/s12957-022-02495-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z, Yang X, Xie H. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Front Oncol 2021;11:743055. [PMID: 34513717 DOI: 10.3389/fonc.2021.743055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
13 Bae B, Song SK, Choi E, Chung CW, Park Y. Secondarily estimated cure fraction and five-year recurrence-free conditional survival probabilities among patients undergoing surgical resection for hepatocellular carcinoma presenting with minor gross vascular invasion. World J Surg Oncol 2021;19:222. [PMID: 34311741 DOI: 10.1186/s12957-021-02331-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]